KEYLYNK-009

About this trial

The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The primary hypotheses are:
– Olaparib plus pembrolizumab prolongs progression-free survival (PFS) compared with chemotherapy plus pembrolizumab.
– Olaparib plus pembrolizumab is non-inferior to chemotherapy plus pembrolizumab in terms of overall survival (OS).
– Olaparib plus pembrolizumab prolongs OS compared with chemotherapy plus pembrolizumab.

Patient Profile

Patients with triple negative breast cancer (TNBC)

Where’s this trial being run?

Cork University Hospital and St Vincents University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: KEYLYNK-009
Number: 19-36
Full Title:

An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009)

Principal Investigator: Dr Janice Walshe (St. Vincent’s University Hospital)
Type: Industry Sponsored
Sponsor:

Merck Sharp & Dohme Corp.

Recruitment Started: Global: Dec-19
Ireland: Nov-20
Global Recruitment Target: 932
Ireland Recruitment Target: